# US 6,261,554 B1 · Compositions for targeted gene delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,261,554 B1
- Document ID: US6261554B1
- Status: Granted
- Kind: B1
- Application number: 09/000,133
- Filed: 1998-02-24
- Granted: 2001-07-17
- Earliest claimed: 1995-07-25
- Assignees: Introgene B.V.
- Inventors: Domenico Valerio; Victor Willem van Beusechem
- Web page: https://patentgrep.com/patent/US6261554B1

## CPC

- C07K 14/005: from viruses
- A61K 47/6898: {using avidin- or biotin-conjugated antibodies}
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C12N 2710/00088: for redistribution
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- C12N 2740/13045: Special targeting system for viral vectors
- C12N 2740/13052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2740/15022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2810/855: from receptors; from cell surface antigens; from cell surface determinants
- C12N 2810/859: from immunoglobulins
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method of producing viral gene delivery vehicles which can be transferred to pre-selected cell types by using targeting conjugates. The gene delivery vehicles comprise: 1) the gene of interest; 2) a viral capsid or envelope carrying a member of a specific binding pair, the counterpart of which is not directly associated with the surface of the target cell. These vehicles can be made unable to bind to their natural receptor on the cell. The targeting conjugates are composed of the counterpart member of the specific binding pair linked to a targeting moiety which is a cell-type specific ligand. The number of the specific binding pair present on the viral vehicles can be, for example, an immunoglobulin binding moiety, biotin, avidin, or streptavidin. The outer membrane or capsid of the virus may contain a substance which mediates entrance of the gene delivery vehicle into the target cell. Due to the specificity of the ligand, the high affinity of the binding pair and to the inability of the gene delivery vehicle to be targeted when used alone, the universality of the method for gene delivery, together with its high cell type selectively can easily be achieved by the use of various adequate targeting conjugates.

## Claims

### Claim 1

A targeting gene delivery vehicle complex, said targeting gene delivery vehicle complex comprising:
a gene delivery vehicle coupled with a bispecific conjugate, said gene delivery vehicle comprising:
an expressible recombinant nucleic acid molecule encoding a gene product of interest;
a capsid or an envelope having an exterior, said capsid or envelope enveloping said recombinant nucleic acid molecule; and
a first member of a specific binding pair associated with said capsid or envelope exterior, which member of said specific binding pair is not directly associated with a surface of a target cell and wherein said first member of the specific binding pair is naturally or recombinantly expressed on said capsid or envelope exterior;
wherein said bispecific conjugate comprises a second member of said specific binding pair covalently coupled to a targeting moiety capable of binding to a target molecule associated with the surface of the target cell.
